Who’s Hired? Alvotech Names New COO After Refiling Adalimumab
As Strides’ Strategy Head Departs And Haggar Becomes Biocon Director
Executive Summary
Alvotech has appointed a fresh chief operating officer as it continues to pursue a US approval for its adalimumab biosimilar. Meanwhile, Strides Pharma Science’s strategy head has left the company and Nick Haggar has joined Biocon’s board, while US association the AAM has also welcomed new staff.
You may also be interested in...
Alvotech Says Adalimumab Story Is ‘Still Being Written’ Ahead Of ‘Critical’ Inspection
With Alvotech once again asking the US FDA to approve its AVT02 high-concentration interchangeable adalimumab candidate after multiple knockbacks, the company says that the opportunity has not passed as the story of Humira biosimilars is “still being written.”
Teva Doubles Down On Alvotech Biosimilars Partnership
Teva will get more involved in Alvotech’s quality oversight as part of enhancements to the pair’s US biosimilars collaboration that will also see two products added to the deal, as well as a $40m investment in Alvotech from the Israeli giant.
Alvotech And Teva To Miss US Adalimumab Launch After Further FDA Setback
FDA approval for Alvotech and Teva’s AVT02 adalimumab biosimilar has once again failed to materialize as the agency issued another CRL over the product. The setback means the firms will miss their projected launch date of 1 July and will not be part of the pack launching multiple Humira rivals in the coming weeks.